The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitro.

Neuroblastoma is a challenging childhood malignancy, with a very high percentage of patients relapsing following acquisition of drug resistance, thereby necessitating the identification of mechanisms of drug resistance as well as new biological targets contributing to the aggressive pathogenicity of the disease. In order to investigate the molecular pathways that are involved with drug resistance in neuroblastoma, we have developed and characterised cisplatin resistant sublines SK-N-ASCis24, KellyCis83 and CHP-212Cis100, integrating data of cell behaviour, cytotoxicity, genomic alterations and modulation of protein expression. All three cisplatin resistant cell lines demonstrated cross resistance to temozolomide, etoposide and irinotecan, all of which are drugs in re-initiation therapy. Array CGH analysis indicated that resistant lines have acquired additional genomic imbalances. Differentially expressed proteins were identified by mass spectrometry and classified by bioinformatics tools according to their molecular and cellular functions and their involvement into biological pathways. Significant changes in the expression of proteins involved with pathways such as actin cytoskeletal signalling (p = 9.28E-10), integrin linked kinase (ILK) signalling (p = 4.01E-8), epithelial adherens junctions signalling (p = 5.49E-8) and remodelling of epithelial adherens junctions (p = 5.87E-8) pointed towards a mesenchymal phenotype developed by cisplatin resistant SK-N-ASCis24. Western blotting and confocal microscopy of MYH9, ACTN4 and ROCK1 coupled with invasion assays provide evidence that elevated levels of MYH9 and ACTN4 and reduced levels of ROCK1 contribute to the increased ROCK1-independent migratory potential of SK-N-ASCis24. Therefore, our results suggest that epithelial-to-mesenchymal transition is a feature during the development of drug resistance in neuroblastoma.

[1]  J. Inazawa,et al.  Actinin-4 expression in ovarian cancer: a novel prognostic indicator independent of clinical stage and histological type , 2007, Modern Pathology.

[2]  A. G. de Herreros,et al.  Epithelial to mesenchymal transition markers are associated with an increased metastatic risk in primary cutaneous squamous cell carcinomas but are attenuated in lymph node metastases. , 2013, Journal of dermatological science.

[3]  Kohei Miyazono,et al.  Differential Regulation of Epithelial and Mesenchymal Markers by δEF1 Proteins in Epithelial–Mesenchymal Transition Induced by TGF-β , 2007 .

[4]  Robert W. Li,et al.  Pathway analysis identifies perturbation of genetic networks induced by butyrate in a bovine kidney epithelial cell line , 2007, Functional & Integrative Genomics.

[5]  O. Carpén,et al.  Alpha-actinin revisited: a fresh look at an old player. , 2004, Cell motility and the cytoskeleton.

[6]  S. Hirohashi,et al.  Actinin-4 increases cell motility and promotes lymph node metastasis of colorectal cancer. , 2005, Gastroenterology.

[7]  H. Kao,et al.  Alpha-actinin 4 and tumorigenesis of breast cancer. , 2013, Vitamins and hormones.

[8]  A. Vicha,et al.  Characterization of drug-resistant neuroblastoma cell lines by comparative genomic hybridization. , 2005, Neoplasma.

[9]  I. Pastan,et al.  Cross-resistance, cisplatin accumulation, and platinum-DNA adduct formation and removal in cisplatin-sensitive and -resistant human hepatoma cell lines. , 1996, Experimental cell research.

[10]  Raghu Kalluri,et al.  The epithelial–mesenchymal transition: new insights in signaling, development, and disease , 2006, The Journal of cell biology.

[11]  A. G. de Herreros,et al.  Functional Cooperation between Snail1 and Twist in the Regulation of ZEB1 Expression during Epithelial to Mesenchymal Transition* , 2011, The Journal of Biological Chemistry.

[12]  Eduard Batlle,et al.  Snail Induction of Epithelial to Mesenchymal Transition in Tumor Cells Is Accompanied by MUC1 Repression andZEB1 Expression* , 2002, The Journal of Biological Chemistry.

[13]  Fumio Matsumura,et al.  Distinct roles of MLCK and ROCK in the regulation of membrane protrusions and focal adhesion dynamics during cell migration of fibroblasts , 2004, The Journal of cell biology.

[14]  V. Betapudi,et al.  Myosin II Motor Proteins with Different Functions Determine the Fate of Lamellipodia Extension during Cell Spreading , 2010, PloS one.

[15]  A. Puisieux,et al.  Oncogenic roles of EMT-inducing transcription factors , 2014, Nature Cell Biology.

[16]  J. Settleman,et al.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer , 2010, Oncogene.

[17]  T. Tan,et al.  Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients , 2014, EMBO molecular medicine.

[18]  Z. Siddik,et al.  Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.

[19]  A. Evans,et al.  The human non-muscle α-actinin protein encoded by the ACTN4 gene suppresses tumorigenicity of human neuroblastoma cells , 2000, Oncogene.

[20]  O. Delattre,et al.  Molecular cytogenetic characterization of doxorubicin‐resistant neuroblastoma cell lines: Evidence that acquired multidrug resistance results from a unique large amplification of the 7q21 region , 2006, Genes, chromosomes & cancer.

[21]  R. Aft,et al.  Temporal and Spatial Cooperation of Snail1 and Twist1 during Epithelial–Mesenchymal Transition Predicts for Human Breast Cancer Recurrence , 2011, Molecular Cancer Research.

[22]  O. Skalli,et al.  Alpha-actinin 1 and alpha-actinin 4: contrasting roles in the survival, motility, and RhoA signaling of astrocytoma cells. , 2010, Experimental cell research.

[23]  Huamin Wang,et al.  Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. , 2009, Cancer research.

[24]  Helen X. Chen,et al.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. , 2010, The New England journal of medicine.

[25]  Yun Chen,et al.  Micro-RNA-21 regulates the sensitivity to cisplatin in human neuroblastoma cells. , 2012, Journal of pediatric surgery.

[26]  M. Stack,et al.  Motility-related actinin alpha-4 is associated with advanced and metastatic ovarian carcinoma , 2008, Laboratory Investigation.

[27]  J. Maris,et al.  Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Stallings,et al.  Modulation of chemotherapeutic drug resistance in neuroblastoma SK‐N‐AS cells by the neural apoptosis inhibitory protein and miR‐520f , 2015, International journal of cancer.

[29]  K. Djinović-Carugo,et al.  α-Actinin structure and regulation , 2008, Cellular and Molecular Life Sciences.

[30]  L. Pieroni,et al.  New insights into neuroblastoma cisplatin resistance: a comparative proteomic and meta-mining investigation. , 2011, Journal of proteome research.

[31]  S. Groshen,et al.  Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. , 1998, Cancer research.

[32]  A. Satelli,et al.  Vimentin in cancer and its potential as a molecular target for cancer therapy , 2011, Cellular and Molecular Life Sciences.

[33]  E. Asselin,et al.  Keratin 8 and 18 Loss in Epithelial Cancer Cells Increases Collective Cell Migration and Cisplatin Sensitivity through Claudin1 Up-regulation* , 2013, The Journal of Biological Chemistry.

[34]  Andrea Urbani,et al.  A proteomic investigation into etoposide chemo‐resistance of neuroblastoma cell lines , 2005, Proteomics.

[35]  Erik Sahai,et al.  Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis , 2003, Nature Cell Biology.

[36]  D. Lauffenburger,et al.  Cell Migration: A Physically Integrated Molecular Process , 1996, Cell.

[37]  Ester Sánchez-Tilló,et al.  EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness , 2012, Cellular and Molecular Life Sciences.

[38]  P. Hains,et al.  Proteome Analysis of Vinca Alkaloid Response and Resistance in Acute Lymphoblastic Leukemia Reveals Novel Cytoskeletal Alterations* , 2003, Journal of Biological Chemistry.

[39]  M. Michaelis,et al.  Chemotherapy-associated angiogenesis in neuroblastoma tumors. , 2012, The American journal of pathology.

[40]  A. Horiguchi,et al.  Increased expression of α-actinin-4 is associated with unfavorable pathological features and invasiveness of bladder cancer. , 2013, Oncology reports.

[41]  M. Olson,et al.  Rho‐associated kinases in tumorigenesis: re‐considering ROCK inhibition for cancer therapy , 2012, EMBO reports.

[42]  Miguel Vicente-Manzanares,et al.  Myosin II in mechanotransduction: master and commander of cell migration, morphogenesis, and cancer , 2013, Cellular and Molecular Life Sciences.

[43]  A. Vicha,et al.  Changes in MYCN expression in human neuroblastoma cell lines following cisplatin treatment may not be related to MYCN copy numbers. , 2013, Oncology reports.

[44]  F. Berthold,et al.  Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Yu-Li Wang,et al.  Cortical Actin Turnover during Cytokinesis Requires Myosin II , 2005, Current Biology.

[46]  H. Doerr,et al.  Onconase induces caspase-independent cell death in chemoresistant neuroblastoma cells. , 2007, Cancer letters.

[47]  R. Blaheta,et al.  Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: A preclinical model , 2003, International journal of cancer.

[48]  R. Stallings,et al.  MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-β signalling pathway. , 2012, Carcinogenesis.

[49]  R. Stallings,et al.  Chromosomal and MicroRNA Expression Patterns Reveal Biologically Distinct Subgroups of 11q− Neuroblastoma , 2010, Clinical Cancer Research.

[50]  Lucila Ohno-Machado,et al.  Snail2 is an essential mediator of Twist1-induced epithelial mesenchymal transition and metastasis. , 2011, Cancer research.

[51]  Jean Paul Thiery,et al.  Epithelial-mesenchymal transitions: insights from development , 2012, Development.

[52]  M. Madonna,et al.  Differential effect of long-term drug selection with doxorubicin and vorinostat on neuroblastoma cells with cancer stem cell characteristics , 2013, Cell Death and Disease.

[53]  Yang Liu,et al.  Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment. , 2007, Cancer treatment reviews.

[54]  Michael M Gottesman,et al.  Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes , 2012, Pharmacological Reviews.

[55]  Miguel Vicente-Manzanares,et al.  Non-muscle myosin II takes centre stage in cell adhesion and migration , 2009, Nature Reviews Molecular Cell Biology.

[56]  R. Breitling,et al.  Chemoresistance acquisition induces a global shift of expression of aniogenesis-associated genes and increased pro-angogenic activity in neuroblastoma cells , 2009, Molecular Cancer.

[57]  R. Rosenberg,et al.  Correlation of double-minute chromosomes with unstable multidrug cross-resistance in uptake mutants of neuroblastoma cells. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[58]  S. Kaneko,et al.  Epithelial-mesenchymal transition-related gene expression as a new prognostic marker for neuroblastoma , 2012, International journal of oncology.

[59]  J. Inazawa,et al.  Different drug sensitivity in two neuroblastoma cell lines established from the same patient before and after chemotherapy , 1991, International journal of cancer.

[60]  Kakajan Komurov,et al.  Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes , 2010, Proceedings of the National Academy of Sciences.

[61]  P B Laub,et al.  Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. , 1997, Cancer research.